Synuclein
This 3-day meeting includes sessions on the physiology, structure and pathology of alpha-synuclein as well as the development of therapeutics and biomarkers for alpha-synucleinopathies, and provides a platform for discussion on the latest developments in the field from fundamental discoveries to
translational studies.
This 3-day meeting includes sessions on the physiology, structure and pathology of alpha-synuclein as well as the development of therapeutics and biomarkers for alpha-synucleinopathies, and provides a platform for discussion on the latest developments in the field from fundamental discoveries to
translational studies.
We are sponsors at this event!
Come and meet our team to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, high-content imaging applications and cell therapies.
Arrange a meeting